📋 15 Things to Know About the Two New Alzheimer’s Drugs (AARP Article)

Content starts here

CLOSE ×

AARP MEMBERSHIP

Join AARP for just $15 for your first year when you sign up for automatic renewal. Gain instant access to exclusive products, hundreds of discounts and services, a free second membership, and a subscription to AARP The Magazine.

Join Now

Renew Now

You're this close to getting so much more ...

Get access to this and all Members-Only discussions, plus a world of member Benefits when you Join AARP!

Become an AARP Member for $12 Already a member? Login >

Members Only

My Settings Guidelines

📋 15 Things to Know About the Two New Alzheimer’s Drugs (AARP Article)

*** There are 4 comments so far on the AARP WEBSITE. Stop by to read comments and add yours. ***

FROM THE ARTICLE - SEE ARTICLE FOR MORE!!!

These drugs are so new, many doctors aren’t prepared with answers to patients’ questions.

By Marlene Cimons. Reviewed by Ariel R. Green, M.D., Ph.D.

Published November 06, 2024.

For the first time in history, doctors who care for people with Alzheimer’s have access to two medications that may be able to modestly slow the progression of the disease — at least for some patients.

The two drugs — Leqembi (lecanemab) and Kisunla (donanemab) — are “transformational,” says Paul E. Schulz, M.D., professor of neurology and director of the Neurocognitive Disorders Center at the McGovern Medical School at UTHealth Houston. “They provide the first inkling that we are on the right path, which gives us great hope that we can continue to tweak things and improve the effects.

https://www.aarp.org/health/conditions-treatments/info-2024/leqembi-kisunla-alzheimers-drugs.html